Results 71 to 80 of about 437,313 (161)

Shared neural signatures of photophobia in migraine and post-traumatic headache: a task-based fMRI study

open access: yesThe Journal of Headache and Pain
Background Persistent post-traumatic headache (PTH) and migraine frequently present with photic hypersensitivity that exacerbates headache symptoms.
Rune Häckert Christensen   +4 more
doaj   +1 more source

Medication Overuse Headache: A Trap for the Headache Patients

open access: diamond, 2013
Aminur Rahman   +3 more
openalex   +2 more sources

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study

open access: yesThe Journal of Headache and Pain
Objective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab.
Faisal Mohammad Amin   +4 more
doaj   +1 more source

PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial

open access: yesThe Journal of Headache and Pain
Background Calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) are key pathogenic drivers of migraine.
Mohammad Al-Mahdi Al-Karagholi   +4 more
doaj   +1 more source

fMRI Reveals Abnormal Attentional Networks in People with Migraine Headache in Between Headache Attacks

open access: gold, 2015
Mickleborough Marla   +5 more
openalex   +1 more source

Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization

open access: yesThe Journal of Headache and Pain
Background Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology, but challenges ...
Alicia Alpuente   +5 more
doaj   +1 more source

Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response

open access: yesThe Journal of Headache and Pain
Background Atogepant is approved for migraine prevention and has shown strong efficacy in clinical trials. However, its effectiveness following failure of anti-CGRP monoclonal antibodies (MAbs) has not been evaluated in large real-world populations ...
Albert Muñoz-Vendrell   +31 more
doaj   +1 more source

Home - About - Disclaimer - Privacy